Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab improves quality of life in ulcerative colitis

Infliximab therapy improves health-related quality of life in ulcerative colitis patients, shows the latest issue the American Journal of Gastroenterology.

News image

fiogf49gjkf04

Dr Brian Feagan and colleagues from Canada evaluated the impact of infliximab induction and maintenance therapy on health-related quality of life in patients with ulcerative colitis.

The research team conducted 2 placebo-controlled, double-blind studies, namely the Active Ulcerative Colitis Trials 1 and 2.

The researchers randomized 728 patients to placebo or infliximab 5 mg/kg or 10 mg/kg.

The IBD questionnaire scores were greater in the infliximab groups
The American Journal of Gastroenterology

Infusions were administered at weeks 0, 2, 6, and every 8 weeks thereafter, up to week 46 in Trial 1 or 22 in Trial 2.

The team analyzed changes in the Inflammatory Bowel Disease (IBD) Questionnaire.

The Medical Outcomes Study 36-Item Short Form Health Survey physical and mental component summary scores were also analyzed.

The researchers found that baseline scores for the pooled patient population indicated substantial impairment in health-related quality of life.

Improvement at week 8 in the total Inflammatory Bowel Disease Questionnaire score was significantly greater in the infliximab 5-mg/kg, and 10-mg/kg groups.

The team noted that improvement at week 8 was also significantly greater in the infliximab 5- and 10-mg/kg groups for the physical and mental component scores.

The researchers observed continued benefit at weeks 30 and 54 with infliximab maintenance therapy.

The team noted that improvement in total Inflammatory Bowel Disease Questionnaire scores correlated with improvement in physical and mental scores, and Mayo score.

Dr Feagan's team concludes, “Infliximab therapy substantially improved health-related quality of life in patients with ulcerative colitis.”

“This benefit was sustained through 1 year with maintenance infliximab therapy.”

Am J Gastroenterol 2007: 102(4): 794-802
02 April 2007

Go to top of page Email this page Email this page to a colleague

 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA
 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us